U.S. Prostate Cancer Diagnostics Market Size & Outlook
U.S. prostate cancer diagnostics market, 2018-2030 (US$M)
Related Markets
U.S. prostate cancer diagnostics market highlights
- The U.S. prostate cancer diagnostics market generated a revenue of USD 3,243.9 million in 2023 and is expected to reach USD 4,653.5 million by 2030.
- The U.S. market is expected to grow at a CAGR of 5.3% from 2024 to 2030.
- In terms of segment, outpatient facilities was the largest revenue generating end use in 2023.
- Home Care is the most lucrative end use segment registering the fastest growth during the forecast period.
Prostate cancer diagnostics market data book summary
| Market revenue in 2023 | USD 3,243.9 million |
| Market revenue in 2030 | USD 4,653.5 million |
| Growth rate | 5.3% (CAGR from 2023 to 2030) |
| Largest segment | Outpatient facilities |
| Fastest growing segment | Home Care |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Hospitals, Outpatient Facilities, Home Care, Research & Manufacturing |
| Key market players worldwide | MDxHealth SA, Myriad Genetics Inc, Abbott Laboratories, Roche Holding AG, Bayer AG, Siemens Healthineers AG ADR, OPKO Health Inc, Exact Sciences Corp, Pfizer Inc |
Other key industry trends
- In terms of revenue, U.S. accounted for 42.0% of the global prostate cancer diagnostics market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In North America, U.S. prostate cancer diagnostics market is projected to lead the regional market in terms of revenue in 2030.
- Canada is the fastest growing regional market in North America and is projected to reach USD 1,123.4 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Prostate Cancer Diagnostics Market Scope
Prostate Cancer Diagnostics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
U.S. prostate cancer diagnostics market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to prostate cancer diagnostics market will help companies and investors design strategic landscapes.
Outpatient facilities was the largest segment with a revenue share of 63.27% in 2023. Horizon Databook has segmented the U.S. prostate cancer diagnostics market based on hospitals, outpatient facilities, home care, research & manufacturing covering the revenue growth of each sub-segment from 2018 to 2030.
Progression of prostate cancer is slow, without exhibiting any symptoms. Therefore, the U.S. Preventive Services Task Force (USPSTF) came up with the following recommendations for men who are at an average or increased risk of prostate cancer.
Men with the age of 55 to 68 years should consider all the risk parameters and consult a doctor to understand the benefits and harms of screening before making individual decisions about screening with PSA. Men who are aged 70+ need not be screened for prostate cancer regularly.
Reasons to subscribe to U.S. prostate cancer diagnostics market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of U.S. prostate cancer diagnostics market databook
-
Our clientele includes a mix of prostate cancer diagnostics market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. prostate cancer diagnostics market , including forecasts for subscribers. This country databook contains high-level insights into U.S. prostate cancer diagnostics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
U.S. prostate cancer diagnostics market size, by end use, 2018-2030 (US$M)
U.S. Prostate Cancer Diagnostics Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
